A Study of SHR-4394 Injection in Subjects With Prostate Cancer

This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4394 injection in subjects with prostate cancer.

Trial Details

NCT ID
NCT06783829
Phase
PHASE1
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • SHR4394
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Age range: 18-85 years old, male;
  • ECOG score for physical condition is 0-1 points;
  • Expected survival period ≥ 6 months;
  • Prostate adenocarcinoma confirmed by histological or cytological examination;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →